Slr Pharma Profile
Key Indicators
- Authorised Capital ₹ 6.70 Cr
as on 23-10-2024
- Paid Up Capital ₹ 2.48 M
as on 23-10-2024
- Company Age 20 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 30.42 Cr
as on 23-10-2024
- Satisfied Charges ₹ 6.40 Cr
as on 23-10-2024
- Revenue 53.04%
(FY 2023)
- Profit 50.30%
(FY 2023)
- Ebitda 31.40%
(FY 2023)
- Net Worth 37.34%
(FY 2023)
- Total Assets 85.00%
(FY 2023)
About Slr Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.70 Cr and a paid-up capital of Rs 2.48 M.
The company currently has active open charges totaling ₹30.42 Cr. The company has closed loans amounting to ₹6.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramireddy Reddy, Lakshmi Ramireddy, and Sathya Reddy serve as directors at the Company.
- CIN/LLPIN
U24239TG2004PTC044219
- Company No.
044219
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Sep 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- LocationHyderabad-038, Telangana
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Slr Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramireddy Reddy  | Director | 19-Feb-2007 | Current |
| Lakshmi Ramireddy | Director | 12-Dec-2013 | Current |
| Sathya Reddy | Director | 18-Oct-2021 | Current |
Financial Performance of Slr Pharma.
Slr Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 53.04% increase. The company also saw a substantial improvement in profitability, with a 50.3% increase in profit. The company's net worth Soared by an impressive increase of 37.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Slr Pharma?
In 2022, Slr Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Pass Pharma (India) Private LimitedActive 15 years 9 months
Lakshmi Ramireddy and Sathya Reddy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Sep 2024 | ₹4.50 Cr | Open |
Others Creation Date: 30 Apr 2024 | ₹15.00 Cr | Open |
Others Creation Date: 06 Dec 2021 | ₹8.00 Cr | Open |
How Many Employees Work at Slr Pharma?
Slr Pharma has a workforce of 27 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Slr Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Slr Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
